Axsome Therapeutics Announces Results of CRESCENDO Narcoleps

77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed...

Related Keywords

United States , United Kingdom , Philadelphia , Pennsylvania , New York , British , Karl Doghramji , Darren Opland , Mark Jacobson , Nasdaq , Axsome Therapeutics Inc , Narcolepsy Network , World Trade Center , Corporate Communications , Drug Administration , Epworth Sleepiness Scale , British Columbia Cognitive Complaints Inventory , Characterizing Patient Perspectives , Unmet Needs , Medical Director , Jefferson Sleep Disorders Center , Thomas Jefferson University , Topline Findings , Narcolepsy Symptoms While , Neutrality Statement , Axsome Therapeutics ,